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INTRODUCTION:
The goal of this proposal is to examine if the expression in human breast cancer biopsies of a novel growth factor, characterized in our laboratory, can be used as an early prognostic factor for estrogen-independence. The critical phase in the diagnosis and therapy of breast cancer is to determine whether a tumor is estrogen responsive or has progressed to estrogen-independence and tamoxifen-resistance. This analysis is important since it will determine if a tumor will be responsive or not to anti-estrogen therapy. Measuring estrogen receptor (ER) and progesterone receptor (PR) expression in the tumor biopsies is done for this purpose. We have cloned a novel tumorigenic growth factor called PC-Cell Derived Growth Factor (PCDGF, granulin precursor) (1) expressed in human breast carcinoma. In ER÷ cells, PCDGF expression is stimulated by estradiol and inhibited by tamoxifen (2) . In ER+ cells, PCDGF mediated estrogen mitogenic activity and overexpression of PCDGF rendered the ER÷ cells estrogen-independent for growth and tamoxifen-resistant (4) while they remained positive for ER and PR. In ERcells, PCDGF is overexpressed. Inhibition of PCDGF expression in ER-cells led to a 90% inhibition of tumor incidence and growth (3) . These results indicated the role of PCDGF in the tumorigenicity of breast carcinoma and identified it as a molecular target of estrogen-independence and tamoxifen resistance that precedes changes in the ER/PR status of the tumors. To test this hypothesis, we have proposed in this concept award to examine the level of expression of PCDGF in paraffin embed breast cancer biopsies and correlate it with clinical parameters as well as with the expression of known prognostic markers of breast cancer.
BODY:
This annual report concerns the studies carried out under a one year Concept Award. The studies supported by this Concept Award have focused on investigating the expression of PCDGF in human breast cancer biopsies to determine whether increase of PCDGF expression correlates with advanced stages of the disease and examine whether PCDGF can be used as a prognostic biomarker for the disease. The approved statement of work and experimental protocol consisted of examining PCDGF expression in paraffin embedded breast tumor biopsies by immunohistochemistry using an anti-PCDGF antibody developed in our laboratory. Even though our original proposal was to limit our study to examining 30 samples, we have extended our studies to 206 archival samples obtained from the surgical pathology archives of the UM Cancer Center and from the Brest Cancer Tumor Bank from the University of Manitoba in Canada. These samples were provided with clinical parameters such as tumor type and grade and lymph node status. Analysis of the staining and pathological interpretation of the data was carried out in collaboration with 0. Ioffe, MD, Breast Pathologist. In addition to measuring PCDGF expression, we also measured expression of estrogen receptor (ER) and progesterone receptor (PR) for the samples for which this information was not provided (UMCC archive biopsies) as well as measuring other markers known that their prognostic value such as p53, erbB2 and the proliferation index Ki67. The results of the study are summarized below.
S
The study on the 206 human breast lesions has shown that PCDGF staining is observed in breast carcinoma whereas it is negative in benign breast epithelium (table 1) . 
CONCLUSION:
Our studies with human breast cancer cell lines have indicated the biological importance of PCDGF in breast cancer tumorigenesis (Lu and Serrero, 2000; 2001) , thereby warranting the investigation of its expression in archived pathological samples. This is the first report describing the expression of PCDGF in human breast tissue. We have shown that PCDGF is not expressed in benign breast epithelium. PCDGF expression was not seen in lobular carcinoma in situ, whereas the majority of invasive lobular carcinoma cases (82%) were either negative or weakly positive. PCDGF expression was found in most cases of in situ and invasive ductal carcinoma. PCDGF was expressed in 80% of IDC with a staining of 2+ or greater in 41% of the cases. In malignant ductal lesions, the degree of PCDGF staining correlated with the histologic grade in DCIS and IDC and with the proliferation (Ki-67) index. We have shown here that PCDGF expression correlates with estrogen and progesterone receptor status in invasive carcinomas, with ER+/PR+ cases having lower PCDGF expression than ER/PRtumors. Our study showed that PCDGF expression correlates with p53 immunoreactivity, which is an accepted indicator of the presence of p53 mutation. p53 positivity has been shown to be associated with poor outcome, especially in lymph node-negative breast cancer (18, 19) , and it is an independent prognostic marker. In summary, our studies provide the first direct evidence of high incidence of PCDGF expression in human breast cancer, in which it correlates with such clinicopathological variables as tumor grade, proliferation index, steroid receptor expression and p53 expression. These characteristics, along with the lack of expression in benign epithelium, and considering our previous studies in breast cancer cell lines suggest the important role of PCDGF in breast cancer and make it a potential target for the development of novel therapy for the treatment of breast cancer. We are also investigating whether PCDGF expression in pathological samples can be used as a predictor to response to therapy thereby making it an important and novel biomarker for breast cancer diagnosis. significantly lower than that of strongly PCDGF-positive carcinomas (48.8, p<0.05).
REFERENCES
PCDGF was expressed in both ER/PR-positive and negative tumors. However, PCDGF expression was significantly higher in ER/PR-negative tumors. Concerning the correlation with p53, a larger percentage of tumors that expressed PCDGF with a staining intensity of 2+ or 3+ were p53-positive (44%) than PCDGF-negative tumors (25%), p<0.05. Interestingly, PCDGF expression in IDC was independent of c-erbB-2 overexpression. 58.5% of tumors that stained for PCDGF with 2+ or 3+ intensity were cerbB-2-negative.
Our studies provide the first direct evidence of high incidence of PCDGF expression in human breast cancer in which it correlates with clinicopathological variables such as tumor grade, steroid receptor status, proliferation index and p53 expression. These characteristics as well as the absence of expression in benign breast tissue suggest an important role of PCDGF in breast cancer pathogenesis and make it a potential novel target for the treatment of breast cancer.
INTRODUCTION
PC cell derived growth factor (PCDGF) is an 88-kDa glycoprotein originally purified from the highly tumorigenic mouse teratoma-derived cell line PC (1, 2) . PCDGF (also known as progranulin) is the largest member of a novel family of cysteine-rich polypeptides that include the 6 kDa epithelins or granulins shown to either promote or inhibit cell growth depending on the cell type tested (3, 4) . Our laboratory was the first to demonstrate the biological activity of PCDGF as a growth promoter for the tumorigenic teratoma PC cells (2) . Others later demonstrated growth-promoting activity of the precursor for other mesenchymal and epithelial cells as well as for pre-implantation embryos (5-7).
Screening of human tumor cell lines for PCDGF expression indicated that it was highly expressed in estrogen receptor-negative (ER) human breast carcinomas whereas it was barely detectable in the non-tumorigenic immortalized mammary epithelial cells (8) .
Inhibition of PCDGF expression by antisense PCDGF cDNA transfection in ER7 human breast carcinoma resulted in a dramatic reduction (more than 98%) in tumor incidence and tumor size when injected in nude mice (8) , implicating PCDGF as a major factor in the maintenance of tumor phenotype. In ER-positive (ERW) cells such as MCF-7 and T47D, PCDGF expression was transcriptionally stimulated by 17-1 estradiol (E2) and inhibited by the anti-estrogen tamoxifen (9) . Recently, we demonstrated that PCDGF mediated E2 mitogenic effect in ERW breast cancer cells (10) . Importantly, overexpression of PCDGF in MCF-7 cells rendered the cells able to proliferate in the absence of estrogen although estrogen receptor expression of the cells remained unchanged (10) . These various studies pointed out that PCDGF was important for the proliferation of breast cancer cells and that increase of PCDGF expression played a major role in the maintenance of the breast cancer phenotype. Based on these observations, the present study was carried out to investigate PCDGF expression in human breast cancer. Ki-67 (MIB-1) is a protein vital to cell proliferation (11); it is a nuclear antigen expressed in all phases of the cell cycle except in GI or Go phase (12) , and is recognized by the antibody MIB-1 in paraffin-embedded archival tissue. High Ki-67 index has been shown to correlate with shortened disease-free survival in breast cancer on multivariate analysis (13) , and with shortened overall and disease-free survival (14) . c-erbB-2 (HER2/neu) is an oncogene that encodes a 185-kDa ligandless receptor tyrosine kinase belonging to the epidermal growth factor receptor superfamily. Its overexpression (seen in 20-30% of breast cancers) has been linked to poor outcome, especially in node-positive patients (15) , whereas its effect on prognosis in node-negative disease has remained controversial (reviewed in (16, 17) ).
p53 is a tumor suppressor gene involved in cell cycle arrest. In breast cancer, it detects high-risk patients, especially if they are node-negative. p53 mutations, which can be identified immunohistochemically, are linked to poor prognosis, high histologic grade and proliferation rate, aneuploidy and steroid receptor negativity (18, 19) . 
MATERIAL AND METHODS

Tissue
Immunohistochemistry
Four-micrometer sections were cut from a representative paraffin block in each case; these sections were immunostained using a standard peroxidase-conjugated streptavidin biotin method. The tissue sections were dewaxed and then rehydrated.
Antigen retrieval was performed using DAKO target retrieval solution (DAKO corporation, Carpenteria, CA). Immunostaining was performed using Ventana autostainer (Ventana, Tucson, AZ). The slides were counterstained with hematoxylin. Appropriate positive and negative controls were included in each run.
Detection of PCDGF by immunohistochemistry PCDGF was detected in tissue sections by immunostaining using an immunoaffinity purified anti-human PCDGF antibody (1 jtg/ml). Purity and specificity of the antibody had been previously determined by SDS-PAGE and western blot analysis.
On western blot analysis of cell lysates, this antibody recognized a single 88 kDa band that could be competed by pre-incubation of the antibody with excess antigen as described previously (10) . PCDGF expression was semiquantitatively categorized as follows: <5% of cells staining -negative, >5% of cells staining -positive; positive staining was graded from weak/focal (1+) to moderate/focal or diffuse (2+) to strong/diffuse (3+).
Detection of Ki-67, p53 and c-erbB2
The proliferation rate was measured by determining the Ki-67 index. Detection of Ki67 was carried out by immunostaining using MIB-1 antibody (DAKO corporation, Carpenteria, CA). Ki67 index was expressed as the percentage of positively staining nuclei per 1000 cells counted. Immunostaining for p53 was performed by using an antip53 antibody from BioGenex Laboratories (San Ramon, CA). Expression of p53 was categorized as follows: <5% of nuclei staining -negative; >5% of nuclei stainingpositive. c-erbB-2 immunostaining was performed using anti-c-erbB-2 antibody (DAKO corporation, Carpenteria, CA). c-erbB-2 expression was assessed by the presence and intensity of the cell membrane staining as follows: <10% staining -negative; >10% cells staining -positive; positive staining was graded from focal, weak, discontinuous membrane staining (1+) to focal moderate continuous membrane reactivity (2+), to homogeneous strong and continuous membrane positivity (3+).
Statistical analysis of the data
Statistical analysis of the data was performed using the ANOVA method, F-test for variances, regression test and chi-square test.
RESULTS
Histopathologic composition of the cases included in the study
The cases examined included 27 ductal carcinoma in situ (DCIS), 12 lobular carcinoma in situ (LCIS), 124 invasive ductal carcinoma (IDC), 17 invasive lobular carcinoma (ILC), and 26 benign breast tissue. The composition, histologic grade and type of the cases examined in this study are shown in Table 1 .
PCDGF expression in human breast tissue and its association with histologic type PCDGF expression was observed in 128 of all 206 cases examined (62%) ( Table   2 ). Most benign breast epithelium was negative for PCDGF (25 out of 26 cases, or 96%), as were most LCIS cases (11 of 12, or 92%). However, the majority of malignant non- Therefore, a larger percentage of tumors that expressed PCDGF with a staining intensity of +2 or + 3 were p53 positive when compared to PCDGF-negative tumors, p=0.02 (Table 6 ).
PCDGF expression and e-erbB-2 overexpression
Among the cases of invasive carcinoma that were negative or weakly positive for PCDGF, 46 of 80 (57.5%) were negative or weakly positive (1+) for c-erbB-2, 25 of 80 (31.3%) were moderately (2+) positive for c-erbB-2, and 19 of 80 cases (23.8%) were strongly c-erbB-2-positive (3+) ( Table 7) . Of the cases moderately to strongly expressing PCDGF (2+/3+), 31 out of 53 (58.5%) did not show immunohistochemical evidence of cerbB-2 overexpression (0/1+ c-erbB-2 staining), and 13 of 53 cases (24.5%) had strong c-erbB-2 reactivity (3+). These results indicate that there is no correlation between c-erbB-2 and PCDGF expression in the invasive mammary carcinomas examined.
DISCUSSION
Our studies with human breast cancer cell lines have indicated the biological importance of PCDGF in breast cancer tumorigenesis (8) (9) (10) , thereby warranting the investigation of its expression in archived pathological samples. This is the first report describing the expression of PCDGF in human breast tissue. We have shown that PCDGF is not expressed in benign breast epithelium. PCDGF expression was not seen in lobular carcinoma in situ, whereas the majority of invasive lobular carcinoma cases (82%) were either negative or weakly positive. PCDGF expression was found in most cases of in situ and invasive ductal carcinoma. PCDGF was expressed in 80% of IDC with a staining of 2+ or greater in 41% of the cases. Therefore, there appears to be a preferential expression of PCDGF in ductal rather than lobular lesions. In malignant ductal lesions, the degree of PCDGF staining correlated with the histologic grade in DCIS and IDC. These data support the fact that in human breast cancer cell lines, the level of PCDGF expression in breast carcinoma cell lines appear to be positively correlated to their tumorigenesis (8) .
Interestingly, PCDGF staining intensity in invasive carcinomas correlated with the proliferation (Ki-67) index. Growth fraction determined by Ki67 in breast carcinomas closely correlates with many others indicators of proliferation, such as S-phase by flow cytometry, (22) thymidine labeling index (23), BrdU index (24, 25) , and mitotic counts (25) . The fact that PCDGF expression correlated with Ki67 index is important since Ki-67 index is an independent factor of poor prognosis, especially in node-negative patients (14, 24) . We have previously shown that PCDGF is a growth stimulator of several breast cancer cell lines and that inhibition of PCDGF expression by antisense transfection or action by neutralizing antibodies resulted in inhibition of in vitro cell proliferation and in vivo tumorigenesis (8, 10) . The finding that PCDGF staining in the current study was significantly associated with Ki-67 index is in agreement with the fact that PCDGF is a growth stimulatory factor for breast cancer.
The correlation of PCDGF expression with histologic grade most likely stems from the growth-stimulating properties of PCDGF since it has been shown that the proliferative rates correlate with histologic grade of invasive and in situ ductal carcinomas (26) (27) (28) .
We have shown here that PCDGF expression correlates with estrogen and progesterone receptor status in invasive carcinomas, with ER+/PR+ cases having lower PCDGF expression than EW/PW tumors. The fact that PCDGF expression is higher in the ER+/PR than in ER+/R+ cases and is similar to PCDGF expression in ER'/PR" tumors, supports the findings by McGuire et al (21) , which showed that ERi/PW breast carcinomas had low response rates to hormonal treatment, akin to ER-/PR-cancers. In their study, McGuire et al. postulated that PR-negativity might be an indicator of a falsepositive estrogen receptor status. Our findings lend further support to this hypothesis.
It is interesting that both ER/PR status and proliferative rate show correlation with PCDGF expression. It has been shown that ER/PR-negative tumors tend to have higher proliferation rates (29) . Our data would suggest that PCDGF contributes to the stimulation of proliferation in steroid receptor-negative tumors to a greater extent than in receptor-positive cancers.
Our study showed that PCDGF expression correlates with p53 immunoreactivity, which is an accepted indicator of the presence of p53 mutation. p53 positivity has been shown to be associated with poor outcome, especially in lymph node-negative breast cancer (18, 19) , and it is an independent prognostic marker. Interestingly, p53 has been shown to directly correlate with Ki-67 index, and not with c-erbB-2 status (30), similar to PCDGF in our study.
Since PCDGF and c-erbB-2 are both implicated in the activation of growth promoting signaling pathways, the lack of significant association between PCDGF and cerbB-2 in the cases studied here is interesting. c-erbB-2 overexpression, often the result of gene amplification, is associated with increased tumor growth rate, enhanced metastatic rate and shorter disease-free and overall survival rate (2, 16, 31, 32) , although c-erbB-2 status has not been consistently proven to represent an independent prognostic indicator (33) . The lack of correlation between PCDGF and c-erbB-2 expression is in agreement with results of our previous studies of human breast cancer cell lines, in which we have shown that high PCDGF expression could be observed in cells that did not express c-erbB-2 (MDA-MB-468 cells) as well as in cells reported to express c-erbB-2 such as MDA-MB-453 (10) . The fact that PCDGF is overexpressed in IDC that are negative or weakly positive for c-erbB-2 would suggest that these two growth factor signaling pathways might be distinct and activated independently from each other. This possibility is presently investigated in detail in our laboratory.
Co-expression of epidermal growth factor (EGF) receptors and transforming growth factor alpha (TGF-alpha) has been shown to constitute an adverse prognostic feature for breast cancer patients (34, 35) . Although no correlation was found between PCDGF and c-erbB-2 expression, it should be pointed out that 24.5% of the cases examined were strongly positive for both PCDGF and c-erbB-2. Experiments are currently underway to investigate the prognostic significance of PCDGF expression either alone or in combination with c-erbB-2 in breast cancer.
The difference in PCDGF expression in invasive lobular and ductal carcinomas is of considerable interest. Although the prognosis of IDC and ILC is essentially identical if matched by stage (36, 37) , the proliferation rates of ILC as measured by mitotic index, Ki-67 index, AgNOR measurement (24, 38) as well as S-phase fraction determination by flow cytometry (39) have been reported to be significantly lower than those of IDC.
Since we have previously shown that PCDGF is a growth stimulator (8, 10) , the relative lack of PCDGF expression in ILC certainly correlates with the low proliferation rates of these tumors. LCIS have been reported to have extremely low proliferation rates, (38, 40) similar to those of benign breast epithelium. These findings would certainly correlate with the lack of PCDGF expression in both benign breast epithelium and LCIS.
In summary, our studies provide the first direct evidence of high incidence of PCDGF expression in human breast cancer, in which it correlates with such clinicopathological variables as tumor grade, proliferation index, steroid receptor expression and p53 expression. These characteristics, along with the lack of expression in benign epithelium, and considering our previous studies in breast cancer cell lines suggest the important role of PCDGF in breast cancer and make it a potential target for the development of novel therapy for the treatment of breast cancer. Immunohistochemical expression of PCDGF significantly correlates with nuclear grade of DCIS (p<0.05). 
